Back to search results

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Abroad (travel likely)Recruiting

Conditions

Breast Cancer · Cancer of the Breast

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Washington University School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Nusayba Bagegni, M.D.) · nbagegni@wustl.edu · 314-273-3022
    Contact: Principal Investigator (Nusayba Bagegni, M.D.)
    Foluso Ademuyiwa, M.D., MPH (Sub-investigator)
    Ron Bose, M.D. (Sub-investigator)
    Katherine Clifton, M.D. (Sub-investigator)
    Andrew Davis, M.D. (Sub-investigator)
    Ashley Frith, M.D. (Sub-investigator)
    Cynthia Ma, M.D., Ph.D. (Sub-investigator)
    Lindsay Peterson, M.D. (Sub-investigator)
    Rama Suresh, M.D. (Sub-investigator)
    Katherine Weilbaecher, M.D. (Sub-investigator)
    Jingqin (Rosy) Luo, Ph.D. (Sub-investigator)
Study leads

  • Nusayba Bagegni, M.D.

    Principal Investigator

    Washington University School of Medicine

View source on ClinicalTrials.gov(opens in a new tab)